Allergan PLC (AGN)

pos +1.40
Today's Range: 252.64 - 256.80 | AGN Avg Daily Volume: 2,224,000
Last Update: 07/25/17 - 2:55 PM EDT
Volume: 1,550,464
YTD Performance: 20.72%
Open: $254.00
Previous Close: $253.52
52 Week Range: $184.50 - $261.27
Oustanding Shares: 335,867,027
Market Cap: 84,292,547,766
6-Month Chart
TheStreet Ratings Grade for AGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 8 8 10
Moderate Buy 3 3 3 3
Hold 3 3 2 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.61 1.61 1.50 1.53
Latest Dividend: 0.70
Latest Dividend Yield: 1.12%
Dividend Ex-Date: 05/16/17
Price Earnings Ratio: -23.65
Price Earnings Comparisons:
AGN Sector Avg. S&P 500
-23.65 8.40 30.80
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
6.98% 1.82% 15.93%
Revenue -3.30 0.70 0.19
Net Income 282.20 0.20 0.00
EPS 281.40 -8.20 0.00
Earnings for AGN:
Revenue 14.57B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $3.95 $4.17 $16.07 $18.02
Number of Analysts 17 17 18 18
High Estimate $4.19 $4.26 $16.23 $18.60
Low Estimate $3.76 $3.98 $15.57 $17.18
Prior Year $3.35 $3.32 $13.51 $16.07
Growth Rate (Year over Year) 17.98% 25.58% 18.94% 12.16%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
"Keep the juices flowin' by janglin' round gently as you move." -- Jonathan Heller,  Catch The Wisdom   As of …

Allergan Break Out Real Money Pro($)

Allergan (AGN) breaks out above resistance. I added. Back to medium sized. AGN data by YCharts

Midday Musings Real Money Pro($)

State of play:   * Gold beginning to spike (now up $7) with SPDR Gold Trust ETF (GLD) trading over $119, up 90 cents). As a…

State of Play Real Money Pro($)

Little price movement over the last few hours. I haven't executed a trade as I make my way back to my office. Dillard's (DDS) is stil…

3 Biotechs to Buy This Summer Real Money Pro($)

These companies will do well, despite a range bound sector.
Yesterday's market advance was likely a function of a more dovish Janet Yellen (delivered without comment). It is clear that the Fed has no clue of where its neutral rate is.
Days like this remind you why you stay in.
"If it is what you say I love it...." - Donald Trump Jr Risk Happens Fast -- and the reverberations of today's disclosures may…

My Takeaways and Observations Real Money Pro($)

"I never knew how easy the game of baseball was until I entered the broadcasting booth." -- Mickey Mantle While the markets were r…
The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Columnist Conversations

COST is beginning to firm up near the $150.00 area. The stock bottomed here at last December's lows before exp...
We like this move today on good turnover and strong option flow. BOUGHT FCX OCT 15 CALL AT 1.04
View Chart »  View in New Window » So far we are holding key support in this one.  Target...
Ahead of Wednesday's earnings report(pre open)GD is on its way to its best close of the year(new all time high...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.